

Evgen Pharma plc
("Evgen" or the "Company")

**Posting of Annual Report and
Notice of AGM**

Alderley Park, UK - 20 June 2023: Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines for the treatment of cancer and other indications, announces that its Annual Report and Accounts for the year ended 31 March 2023 have been posted to shareholders and are now available on the Company website at <https://evgen.com/investors/>.

Additionally, the Company's AGM will take place on 20 July, 2023 at 2pm BST at the Block 11 Lecture Theatre, Alderley Park, Congleton Road, Nether Alderley, Cheshire, SK10 4TG.

After the AGM, the Company will host a virtual presentation and Q&A for investors via the Investor Meet Company platform, at 4pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard until 9am the day before the meeting, or at any time during the live presentation.

Investors can sign up to the Investor Meet Company platform for free and meet Evgen via this [link](#). Investors who already follow Evgen on the platform will automatically be invited.

-Ends-

Enquiries:

Evgen Pharma plc
Dr Huw Jones, CEO
Richard Moulson, CFO

[+44 1625 466591](tel:+441625466591)

FinnCap (Nominated Advisor and Broker)
Geoff Nash / Teddy Whitley (Corporate Finance)
Alice Lane / Nigel Birks (ECM)

[+44 20 7220 0500](tel:+442072200500)

Instinctif Partners
Melanie Toyne-Sewell / Rozi Morris / Adam Loudon

[+44 207 457 2020](tel:+442074572020)
evgen@instinctif.com

Notes to Editors

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. With respect to areas outside of oncology and inflammation, Evgen signed an out-licensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology. More recently Evgen completed an out-licensing transaction with Stalicia SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of \$160.5m and a double-digit royalty on sales.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOABDGDLLUDDGXG